{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:09:46Z","timestamp":1780643386536,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejphar.2014.04.015","type":"journal-article","created":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T11:30:10Z","timestamp":1398079810000},"page":"410-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques"],"prefix":"10.1016","volume":"740","author":[{"given":"Thomas P.","family":"Roddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiana","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Kulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesaire","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gewain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian K.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Vachal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen O.","family":"Akinsanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele A.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Previs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayes M.","family":"Dansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.04.015_bib1","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.04.015_bib2","unstructured":"Barylski M., Toth P.P., Nikolic D., Banach M., Rizzo M., Montalto G., Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality, Best Pract. Res. Clin. Endocrinol. Metab., 10.1016\/j.beem.2013.11.001, in press"},{"key":"10.1016\/j.ejphar.2014.04.015_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2014.04.015_bib4","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.04.015_bib5","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1194\/jlr.M016410","article-title":"Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters","volume":"52","author":"Castro-Perez","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib6","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2009.10.007","article-title":"Cardiovascular disease risk factors: epidemiology and risk assessment","volume":"105","author":"Dahlof","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"33","key":"10.1016\/j.ejphar.2014.04.015_bib7","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"PNAS."},{"key":"10.1016\/j.ejphar.2014.04.015_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12265-011-9340-9","article-title":"Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples","volume":"5","author":"Han","year":"2012","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib9","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/S0022-2275(20)39201-4","article-title":"Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons","volume":"36","author":"Hultin","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2014.04.015_bib11","first-page":"E209","article-title":"Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantification","volume":"302","author":"Jensen","year":"2012","journal-title":"Am. J. Physiol.: Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2014.04.015_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1476-511X-10-38","article-title":"Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents","volume":"10","author":"Konrad","year":"2011","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejphar.2014.04.015_bib13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2014.04.015_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/rcm.5296","article-title":"A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography\/tandem mass spectrometry","volume":"26","author":"Lassman","year":"2012","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejphar.2014.04.015_bib15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2014.04.015_bib16","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1194\/jlr.M007468","article-title":"Biochemical characterization of cholesteryl ester transfer protein inhibitors","volume":"51","author":"Ranalletta","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib17","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.04.015_bib18","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1194\/jlr.M041541","article-title":"in vivo effects of anacetrapib on pre-beta HDL: improvement in HDL remodeling without effects on cholesterol absorption","volume":"54","author":"Wang","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1194\/jlr.M019927","article-title":"Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia","volume":"53","author":"Yin","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2014.04.015_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes","volume":"8","author":"Zhang","year":"2012","journal-title":"Int. J. Biol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:19:28Z","timestamp":1764263968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":20,"alternative-id":["S0014299914002994"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.04.015","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}